- Previous Close
1,487.00 - Open
1,467.00 - Bid 1,459.00 x --
- Ask 1,462.00 x --
- Day's Range
1,441.00 - 1,480.00 - 52 Week Range
1,413.00 - 1,824.00 - Volume
164,700 - Avg. Volume
125,822 - Market Cap (intraday)
27.849B - Beta (5Y Monthly) 0.53
- PE Ratio (TTM)
7.45 - EPS (TTM)
196.35 - Earnings Date May 8, 2025 - May 12, 2025
- Forward Dividend & Yield 85.00 (5.72%)
- Ex-Dividend Date Jun 27, 2025
- 1y Target Est
1,400.00
Mizuho Medy Co.,Ltd. researches and develops, manufactures, and sells in-vitro diagnostic products and related scientific and technical information services primarily in Japan. The company provides immunoassay test products, such as influenza virus kits; RS virus and human metapneumovirus antigen test kits; streptococcus pneumoniae antigen and legionella antigen test kits; mycoplasma pneumoniae antigen test kits; adenovirus antigen test kits; rotavirus and adenovirus antigen test kits; norovirus antigen test kits; group a streptococcal antigen test kits; pregnancy test kits; ovulation test kits; and fecal occult blood test kits. It also offers gene analysis instrument; SARS-CoV-2 detection kits; and mycoplasma pneumoniae nucleic acid kits. In addition, the company engages in import and export activities. It also operates in the United States, Belgium, Finland, Netherlands, Taiwan, Thailand, etc. Mizuho Medy Co.,Ltd. was incorporated in 1977 and is headquartered in Tosu, Japan.
www.mizuho-m.co.jp--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 4595.T
View MorePerformance Overview: 4595.T
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4595.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4595.T
View MoreValuation Measures
Market Cap
27.85B
Enterprise Value
16.70B
Trailing P/E
7.32
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.51
Price/Book (mrq)
1.76
Enterprise Value/Revenue
1.51
Enterprise Value/EBITDA
3.15
Financial Highlights
Profitability and Income Statement
Profit Margin
33.01%
Return on Assets (ttm)
15.49%
Return on Equity (ttm)
22.85%
Revenue (ttm)
11.43B
Net Income Avi to Common (ttm)
3.77B
Diluted EPS (ttm)
196.35
Balance Sheet and Cash Flow
Total Cash (mrq)
11.25B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
2.41B